Year

2015
2,000L Demonstration Batch Completed at Lonza, Houston FacilitySAN DIEGO, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has conducted initial scale up of its viral manufacturing process for MYDICAR (AAV1/SERCA2a) to commercial scale.
SAN DIEGO, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has been added to the NASDAQ Biotechnology Index, through the annual update that will become effective prior to market open on Monday, December 22, 2014.The NASDAQ...
1 10 11 12

Nyheder

Professor førte fransk forskerkvartet på sporet af sjælden hjernesygdom
19. marts 2019
Lundbeckfonden bag største serie A-investering i dansk biotek nogensinde
11. marts 2019
Lundbeckfonden belønner pioner-udredning af blodpropper i de små blodkar i hjernen
5. marts 2019

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge